AR057900A1 - Derivados de 9- cloro-15-desoxiprostaglandina, procesos para su preparacion y su uso como medicamento - Google Patents
Derivados de 9- cloro-15-desoxiprostaglandina, procesos para su preparacion y su uso como medicamentoInfo
- Publication number
- AR057900A1 AR057900A1 ARP060105047A ARP060105047A AR057900A1 AR 057900 A1 AR057900 A1 AR 057900A1 AR P060105047 A ARP060105047 A AR P060105047A AR P060105047 A ARP060105047 A AR P060105047A AR 057900 A1 AR057900 A1 AR 057900A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- hydroxy
- substituted
- alkoxy
- Prior art date
Links
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 150000003254 radicals Chemical class 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 abstract 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 abstract 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000003435 aroyl group Chemical group 0.000 abstract 1
- -1 carboxy, hydroxy Chemical group 0.000 abstract 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
Reivindicacion 1: Compuestos caracterizados porque responden a la formula general (1) donde R1 es un grupo CH2OH, -COOR2, -CONHR2 o -CONHR3; R2 es un H alquilo C1-10 que es lineal o ramificado, opcionalmente mono a poliinsaturado y está opcionalmente mono a polisustituido con halogeno, alcoxi C1-4, arilo C3-10 sustituido o aroilo C3-10 opcionalmente sustituido, di-C1-5-alquilamino o tri-C1-5 alquilamino, cicloalquilo C3-10 que está opcionalmente sustituido con alquilo C1-4; arilo C3-10 que está opcionalmente sustituido con fenilo, 1-naftilo, 2-naftilo que a su vez puede estar sustituido en la posicion 3 y en la posicion 4 con F, Cl, alcoxi o trifluorometilo o en la posicion 4 con hidroxi, halogeno, fenilo, uno o más grupos alquilo C1-4, clorometilo, fluorometilo, trifluorometilo, carboxi, hidroxi o alcoxi C1-4 o un heterocicloalquilo C3-7; R3 es un ácido carboxílico C1-15 o ácido sulfonico C1-15; A es un grupo cis-CH=CH- o -CH2-CH2-; B es un grupo trans-CH=CH- o -CH2- CH2-; W es un alquileno C2-6; R4 es un grupo hidroxi, un radical O-R6 o O-R7 donde R6 es un radical tetrahidropiranilo, tetrahidrofuranilo, trimetilsililo, ter-butildimetilsililo, ter-butildifenilsililo o tribencilsililo y R7 es un ácido carboxílico C1-15; R5 es H, un grupo alquilo C1-10 o alquenilo C1-10; n es el numero 1-4; y las sales de los mismos y los ciclodextrinclatratos de los mismos con bases aceptables para uso fisiologico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05090321A EP1816121B1 (en) | 2005-11-21 | 2005-11-21 | 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057900A1 true AR057900A1 (es) | 2007-12-26 |
Family
ID=35744724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060105047A AR057900A1 (es) | 2005-11-21 | 2006-11-17 | Derivados de 9- cloro-15-desoxiprostaglandina, procesos para su preparacion y su uso como medicamento |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1816121B1 (es) |
| JP (1) | JP2009516665A (es) |
| KR (1) | KR20080068877A (es) |
| CN (1) | CN101312946A (es) |
| AR (1) | AR057900A1 (es) |
| AT (1) | ATE388936T1 (es) |
| AU (1) | AU2006314733A1 (es) |
| BR (1) | BRPI0618756A2 (es) |
| CA (1) | CA2629031A1 (es) |
| CR (1) | CR10006A (es) |
| DE (1) | DE602005005355T2 (es) |
| DK (1) | DK1816121T3 (es) |
| DO (1) | DOP2006000257A (es) |
| EA (1) | EA200801211A1 (es) |
| EC (1) | ECSP088472A (es) |
| ES (1) | ES2302122T3 (es) |
| GT (1) | GT200800066A (es) |
| IL (1) | IL190596A0 (es) |
| NO (1) | NO20082838L (es) |
| PE (1) | PE20070644A1 (es) |
| PL (1) | PL1816121T3 (es) |
| PT (1) | PT1816121E (es) |
| TW (1) | TW200738611A (es) |
| UY (1) | UY29925A1 (es) |
| WO (1) | WO2007057232A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5271272B2 (ja) * | 2006-11-16 | 2013-08-21 | ジェンムス ファーマ インコーポレイティド | Ａ型インフルエンザウィルス感染の治療のための薬剤としてのｅｐ２およびｅｐ４作動薬 |
| EP2149552A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors |
| EP2149554A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma Aktiengesellschaft | Indolylamide als Modulatoren des EP2-Rezeptors |
| EP2149551A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors |
| DE102009049662A1 (de) | 2009-10-13 | 2011-04-14 | Bayer Schering Pharma Aktiengesellschaft | 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten |
| TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑 |
| EP4103192A4 (en) | 2020-02-12 | 2024-02-21 | Cytoagents, Inc. | COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTIONS |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4171331A (en) * | 1978-06-05 | 1979-10-16 | Miles Laboratories, Inc. | 1 And 2-substituted analogues of certain prostaglandins |
| DE2950027A1 (de) * | 1979-12-10 | 1981-06-11 | Schering Ag Berlin Und Bergkamen, 1000 Berlin | 9-chlor-prostaglandinderivate, verfahren zur herstellung und verwendung als arzneimittel |
| JP3162668B2 (ja) * | 1997-02-04 | 2001-05-08 | 小野薬品工業株式会社 | ω−シクロアルキル−プロスタグランジンＥ２誘導体 |
| JP2000095755A (ja) * | 1998-07-21 | 2000-04-04 | Ono Pharmaceut Co Ltd | ω―シクロアルキル―プロスタグランジンＥ１誘導体、その製造方法およびその誘導体を有効成分とする医薬組成物 |
| WO2002009717A1 (en) * | 2000-07-31 | 2002-02-07 | Ono Pharmaceutical Co., Ltd. | Erectile dysfunction remedies containing prostaglandin derivatives as the active ingredient |
-
2005
- 2005-11-21 AT AT05090321T patent/ATE388936T1/de not_active IP Right Cessation
- 2005-11-21 DK DK05090321T patent/DK1816121T3/da active
- 2005-11-21 PT PT05090321T patent/PT1816121E/pt unknown
- 2005-11-21 ES ES05090321T patent/ES2302122T3/es not_active Expired - Lifetime
- 2005-11-21 DE DE602005005355T patent/DE602005005355T2/de not_active Expired - Lifetime
- 2005-11-21 PL PL05090321T patent/PL1816121T3/pl unknown
- 2005-11-21 EP EP05090321A patent/EP1816121B1/en not_active Expired - Lifetime
-
2006
- 2006-11-13 TW TW095141974A patent/TW200738611A/zh unknown
- 2006-11-17 AR ARP060105047A patent/AR057900A1/es unknown
- 2006-11-17 UY UY29925A patent/UY29925A1/es not_active Application Discontinuation
- 2006-11-20 DO DO2006000257A patent/DOP2006000257A/es unknown
- 2006-11-20 AU AU2006314733A patent/AU2006314733A1/en not_active Abandoned
- 2006-11-20 KR KR1020087012052A patent/KR20080068877A/ko not_active Withdrawn
- 2006-11-20 JP JP2008540536A patent/JP2009516665A/ja active Pending
- 2006-11-20 CN CNA2006800435083A patent/CN101312946A/zh active Pending
- 2006-11-20 CA CA002629031A patent/CA2629031A1/en not_active Abandoned
- 2006-11-20 WO PCT/EP2006/011378 patent/WO2007057232A1/en not_active Ceased
- 2006-11-20 EA EA200801211A patent/EA200801211A1/xx unknown
- 2006-11-20 BR BRPI0618756-0A patent/BRPI0618756A2/pt not_active Application Discontinuation
- 2006-11-20 PE PE2006001471A patent/PE20070644A1/es not_active Application Discontinuation
-
2008
- 2008-04-03 IL IL190596A patent/IL190596A0/en unknown
- 2008-05-16 GT GT200800066A patent/GT200800066A/es unknown
- 2008-05-21 CR CR10006A patent/CR10006A/xx not_active Application Discontinuation
- 2008-05-26 EC EC2008008472A patent/ECSP088472A/es unknown
- 2008-06-20 NO NO20082838A patent/NO20082838L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL1816121T3 (pl) | 2008-08-29 |
| CA2629031A1 (en) | 2007-05-24 |
| EA200801211A1 (ru) | 2008-10-30 |
| GT200800066A (es) | 2009-03-12 |
| TW200738611A (en) | 2007-10-16 |
| BRPI0618756A2 (pt) | 2011-09-13 |
| UY29925A1 (es) | 2007-06-29 |
| IL190596A0 (en) | 2008-11-03 |
| PT1816121E (pt) | 2008-05-28 |
| ES2302122T3 (es) | 2008-07-01 |
| DK1816121T3 (da) | 2008-06-16 |
| DOP2006000257A (es) | 2007-06-15 |
| WO2007057232A1 (en) | 2007-05-24 |
| ECSP088472A (es) | 2008-06-30 |
| DE602005005355D1 (de) | 2008-04-24 |
| DE602005005355T2 (de) | 2009-03-26 |
| KR20080068877A (ko) | 2008-07-24 |
| EP1816121B1 (en) | 2008-03-12 |
| AU2006314733A1 (en) | 2007-05-24 |
| NO20082838L (no) | 2008-06-20 |
| EP1816121A1 (en) | 2007-08-08 |
| CN101312946A (zh) | 2008-11-26 |
| ATE388936T1 (de) | 2008-03-15 |
| PE20070644A1 (es) | 2007-07-31 |
| JP2009516665A (ja) | 2009-04-23 |
| CR10006A (es) | 2008-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1109307T1 (el) | Χρηση αδαπαλενιου για τη θεραπεια δερματολογικων διαταραχων | |
| PE20150350A1 (es) | Acidos 5-aminotetrahidroquinolin-2-carboxilicos novedosos y su uso | |
| CO6751287A2 (es) | Composición antigénetica de micobacteria | |
| DK2436275T3 (da) | Lipidsammensætning til forbedring af hjernefunktion | |
| EA201170381A1 (ru) | Получение сквалена из гиперпродуцирующих дрожжей | |
| MX2017009489A (es) | Composicion auto-emulsionante de acido graso ?3. | |
| ES2061472T3 (es) | Concentrado perlescente fluido. | |
| AR057900A1 (es) | Derivados de 9- cloro-15-desoxiprostaglandina, procesos para su preparacion y su uso como medicamento | |
| AR094204A1 (es) | Composiciones para el cuidado oral que contienen haluros de acido amino | |
| BR112014029766A2 (pt) | composições contendo álcoois graxos, tensoativos catiônicos e n-acil-n-metilglucaminas | |
| ES2531009T3 (es) | Análogos sustituidos de dicetopiperazina para su uso como agentes para la administración de fármacos | |
| WO2014039964A3 (en) | Compounds and methods for modulating vascular injury | |
| AR094941A1 (es) | Una composición que comprende un compuesto lipídico, un triglicérido y un tensioactivo, y métodos para usarla | |
| BR112015003330A2 (pt) | sistema de marcação a laser, sistema de registro de marcação a laser, sistema de marcação a laser e manuseio de tira de material, sistema de marcação, método para marcar a laser de uma tira de material de aba e método para controlar um deslocamento de imagem | |
| TW201613559A (en) | Emulsion composition | |
| PE20190969A1 (es) | Acido graso altamente insaturado o ester etilico de acido graso altamente insaturado, con reducidos contaminantes ambientales, y metodo para producir el mismo | |
| BR112013032648A2 (pt) | estrutura de superfície para artigo | |
| BR112016006896A2 (pt) | fibra, manta, lenços umedecidos e processo para melhorar a estabilidade hidrolítica das fibras compreendendo um poliéster alifático | |
| ES2478447T3 (es) | Formulaciones del ácido desoxicólico y sus sales | |
| BR112015025858A2 (pt) | processo e dispositivo para a operação de uma mesa de operação móvel | |
| BR112015027545A2 (pt) | composição de higiene bucal contendo pedra pomes e carbonato de cálcio | |
| BR112018009423A8 (pt) | método de limpeza, e, armazenamento temporário de correias. | |
| UY34455A (es) | Formulación oral compleja que comprende ácido graso omega 3 e inhibidor de la hmg-coa reductasa con estabilidad mejorada | |
| AR038924A1 (es) | Utilizacion del acido 6-[3-(1-adamantil)-4-metoxifenil)-2-naftoico para el tratamiento de desordenes dermatologicos | |
| AR073413A1 (es) | Composicion cosmetica para pieles sensibles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |